PT  - JOURNAL ARTICLE
AU  - Nothelfer, Eva-Maria
AU  - Zitzmann-Kolbe, Sabine
AU  - Garcia-Boy, Regine
AU  - Krämer, Susanne
AU  - Herold-Mende, Christel
AU  - Altmann, Annette
AU  - Eisenhut, Michael
AU  - Mier, Walter
AU  - Haberkorn, Uwe
TI  - Identification and Characterization of a Peptide with Affinity to Head and Neck Cancer
AID  - 10.2967/jnumed.108.058123
DP  - 2009 Mar 01
TA  - Journal of Nuclear Medicine
PG  - 426--434
VI  - 50
IP  - 3
4099  - http://jnm.snmjournals.org/content/50/3/426.short
4100  - http://jnm.snmjournals.org/content/50/3/426.full
SO  - J Nucl Med2009 Mar 01; 50
AB  - Combination therapy has improved the quality of life for patients with squamous cell carcinomas of the head and neck (HNSCCs) but has not decisively changed prognosis. Targeted therapies, which enhance accumulation of the drug in the tumor, may be realized using tumor-specific binding peptides. This paper identifies and characterizes an HNSCC affine peptide. Methods: From a phage library comprising 109 different displayed peptides, 1 peptide was enriched after 5 in vitro selection rounds on HNO223 tumor cells. Subsequently, the gained peptide sequence H2N-SPRGDLAVLGHKY-CONH2 (HBP-1) was synthesized as an amide and labeled with 125I. In vitro studies for binding kinetics and competition were performed with 5 different HNSCC cell lines. Furthermore, the stability of the peptide was evaluated in human serum. The in vivo biodistribution of 131I-labeled peptide was determined in HNSCC tumor–bearing nude mice. The results were further validated in human HNSCC tumor tissue sections using fluorescence-labeled HBP-1. Competition experiments were performed to determine the binding sequence and validate the target. Results: The HBP-1 motif was enriched in 62% of all phages sequenced. Labeled 125I-HBP-1 showed binding to 5 different HNSCC cell lines and a maximum binding to HNO97 cells, with 11% of the applied dose per 106 cells and an inhibitory concentration of 50% of 38.9 nM. Stability experiments in human serum showed a half-life of 55 min. In 2 different HNSCC tumor xenografts, 131I-HBP-1 accumulated rapidly, with stable uptake until 45 min after intravenous application. Peptide immunohistochemistry of HNSCC tissue sections exhibited tumor staining by HBP-1, whereas normal tissue remained negative. Sequence mutation and competition experiments revealed that the intrinsic RGD motif in combination with the intrinsic LXXL motif is responsible for the binding ability of HBP1. The RGDLXXL sequence within this peptide is known and indicates that binding occurs via the αvβ6 rather than the αvβ3 integrin. Conclusion: Within the sequence of HBP-1 is a RGDLXXL motif, and most likely it is targeting the αvβ6 receptor of the integrin family of cell adhesion receptors. HBP-1 represents a promising lead structure for the development of targeted therapies or diagnostic procedures in patients with HNSCC.